A photo of Halima Moncrieffe.

Assistant Professor, UC Department of Pediatrics


About Me


Watch a video to learn more about Halima Moncrieffe, PhD, and her research.

Halima Moncrieffe, PhD, is an immunologist who has basic and translational research interests in mechanisms of autoimmune disease susceptibility and immunopathology. Dr. Moncrieffe studies how genetic and immunological variants contribute to inflammation and response to medication. The term 'idiopathic' in JIA denotes that there is no known cause for this debilitating disease. Dr. Moncrieffe's research helped reveal a putative immunological trigger for childhood arthritis and provides new insights into the complexities of JIA. Dr. Moncrieffe also identified a biomarker (MRP8/14) that is present in the blood of a subgroup of patients with JIA who are more likely to respond to methotrexate treatment. This work has translated from the research laboratory to patients and is available as a clinical test.

Dr. Moncrieffe has national and international leadership roles including as Chair of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) SOP committee, and as an active member of the International Union of Immunological Societies' Clinical Immunology Committee. Dr. Moncrieffe leads workshops on research and leadership, and she is a regularly invited local and international speaker and panelist. Dr. Moncrieffe was selected as a TEDMED Research Scholar for her immunology expertise. Dr. Moncrieffe is an active mentor and her students have continued postgraduate studies, including at Ivy League institutions, to pursue their careers in research, medicine, nursing, and pharmacy.

Research Interests

Precision medicine; functional genomics; health disparities; pediatric autoimmune disease with specialty in juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE)

Academic Affiliation

Assistant Professor, UC Department of Pediatrics

My Education

PhD: Imperial College London, London, United Kingdom.

My Publications

Selected Publication

Association of SLCO1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients. Ramsey, LB; Moncrieffe, H; Smith, CN; Sudman, M; Marion, MC; Langefeld, CD; Becker, ML; Thompson, SD. Acr Open Rheumatology. 2019; 1:58-62.

Identification of enhanced IFN-gamma signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. Throm, AA; Moncrieffe, H; Orandi, AB; Pingel, JT; Geurs, TL; Miller, HL; Daugherty, AL; Malkova, ON; Lovell, DJ; Thompson, SD; et al. JCI insight. 2018; 3.

S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis. Gohar, F; Anink, J; Moncrieffe, H; Van Suijlekom-Smit, LW A; Prince, FH M; van Rossum, MA J; Dolman, KM; Hoppenreijs, EP A H; ten Cate, R; Ursu, S; et al. The Journal of rheumatology. 2018; 45:547-554.

Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci. McIntosh, LA; Marion, MC; Sudman, M; Comeau, ME; Becker, ML; Bohnsack, JF; Fingerlin, TE; Griffin, TA; Haas, JP; Lovell, DJ; et al. Arthritis and Rheumatology. 2017; 69:2222-2232.

Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. Moncrieffe, H; Bennett, MF; Tsoras, M; Luyrink, LK; Johnson, AL; Xu, H; Dare, J; Becker, ML; Prahalad, S; Rosenkranz, M; et al. Rheumatology. 2017; 56:1542-1551.

Autoimmune response to transthyretin in juvenile idiopathic arthritis. Clement, CC; Moncrieffe, H; Lele, A; Janow, G; Becerra, A; Bauli, F; Saad, FA; Perino, G; Montagna, C; Cobelli, N; et al. JCI insight. 2016; 1.

The transcription factor CREM drives an inflammatory phenotype of T cells in oligoarticular juvenile idiopathic arthritis. Ohl, K; Nickel, H; Moncrieffe, H; Klemm, P; Scheufen, A; Foell, D; Wixler, V; Schippers, A; Wagner, N; Wedderburn, LR; et al. Pediatric Rheumatology Online Journal. 2018; 16.

Proceedings of the 2016 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting. Fotis, L; Shaikh, N; Baszis, K; French, A; Tarr, P; Lee, P; Leroux, B; Leahey, H; Yuasa, M; Foster, J; et al. Pediatric Rheumatology Online Journal. 2016; 14.

HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Ombrello, MJ; Remmers, EF; Tachmazidou, I; Grom, A; Foell, D; Haas, J; Martini, A; Gattorno, M; Ozen, S; Prahalad, S; et al. Proceedings of the National Academy of Sciences of USA. 2015; 112:15970-15975.